Collaborative Consult: Cases, Patient Reflection, and Discussions – What’s New in Pediatric Atopic Dermatitis – Tweetorial




Provided by Integrity Continuing Education, Inc.


Supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.


Over 9.8% of children in the United States have atopic dermatitis (AD), which is associated with significant disability and poor quality of life. While progress has occurred in the development of advanced therapies capable of improving response in poorly controlled AD, challenges still exist.

For instance, lack of prescriber confidence due to unfamiliarity of mechanisms of action of new and emerging agents persists. Join us in a Twitter-based tutorial with expert faculty Dr. Anthony Mancini that explores pathophysiology of AD, reviews newly approved therapies and their place in treatment, and covers emerging agents. The latest data will be complemented with a patient ambassador story, sharing a familiy’s experience with AD.


Anthony J. Mancini, MD, FAAP, FAAD
Head, Division of Dermatology
Ann & Robert H. Lurie Children’s Hospital of Chicago
Professor of Pediatrics and Dermatology
Northwestern University Feinberg School of Medicine
Chicago, Illinois


Release date: July 27, 2022
Expiration date: July 27, 2023
Estimated time to complete activity: 30 minutes



This educational activity has been designed to meet the needs of dermatologists, senior dermatology residents, and other members of the healthcare team who manage treatment for patients with AD.


Upon completion of this educational activity, participants should be able to:

  • Describe the immunopathogenesis of AD
  • Summarize current clinical trial data on the safety and efficacy of new and emerging therapies for pediatric AD
  • Apply evidence-based guideline recommendations to the treatment of pediatric AD

There are no fees for participating and receiving CME credit for this activity. During the period of July 27, 2022 through July 27, 2023 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 66% or better.




Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Anthony J. Mancini, MD, FAAP, FAAD
Advisory Boards: Castle Creek, Cassiopea, Novartis
Advisor/Consultant: ParaPRO, Verrica
Speakers Bureau: Novartis, Sanofi Genzyme

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest